Branched-Chain Amino Acids

Phase 2Small molecule

FFudan University

Branched-Chain Amino Acids is one of 58 small molecule programs targeting Concussion. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConcussionActive, not recruiting

EncephalopathyActive, not recruiting

ConcussionPhase 2

Active, not recruiting

EncephalopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

21 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alinia

RRomark Laboratories L.C.

Phase 3

4 4

PROCRIT

WWim Janssens

Phase 3

3 5

Cafcit

KKaken Pharmaceutical

Phase 3

1 6

Yescarta

Gilead

Phase 2

1 7

VSL#3

CCD Pharma India Pvt. Ltd.

Phase 3

2 8

Erythropoietin-Beta

Roche

Phase 3

1 9

Citicoline

UUniversity of Texas Southwestern Medical Center

Phase 3

1 10

Magnesium SO4

HHospital de Base

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Encephalopathy

NCT06483737

Q2 2028

Phase 2Not yet recruiting

Pembrolizumab

NCT07412054

Clinical

Trials by Indication[1]

Concussion1 trial

BCAA Supplementation for Concussion

Completed·—·Phase 2·NCT01860404·42 enrolled

Pembrolizumab1 trial

Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC

Not yet recruiting·FFudan University·Phase 2·NCT07412054·234 enrolled

Encephalopathy1 trial

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06483737·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Branched-Chain Amino Acids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Branched-Chain Amino Acids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Branched-Chain Amino Acids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

Branched-Chain Amino Acids

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Trials by Indication[1]

Concussion1 trial

Pembrolizumab1 trial

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News